• Corcept’s President, Corcept Endocrinology Justin Frederick Gunn filed a Form 3 showing 12,191 shares of common stock.
• Disclosure also lists stock options covering 72,397 shares, with exercise prices of $35.7, $37.94, $60.58.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-414633), on October 05, 2026, and is solely responsible for the information contained therein.